December 31, 2013 | Hadasit Bio-Holdings, the commercialization branch of Hadassah Medical Center, has received NIS 25 million (approx. $7.2 million) from the Office of the Chief Scientist. The funds will be directed towards three of Hadasit’s portfolio companies: Cell Cure, KAHR Medical and Enlivex Therapeutics.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

$10M For Cyber Company That Protects Small Businesses
January 31, 2023

Phone-Block Technology For School Bus Drivers
January 31, 2023

Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023

People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments